ArticleIBRO neuroscience reports2025
Striatal metabolomic alterations in a mouse model of Parkinson's disease: A comprehensive liquid chromatography-mass spectrometry analysis.
Article in IBRO neuroscience reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Parkinson's disease (PD) is a chronic neurodegenerative disorder characterized pathologically by the progressive loss of dopaminergic neurons in the substantia nigra pars compacta, leading to a significant decline in striatal dopamine levels. This study aims to systematically analyze alterations in striatal metabolites across different stages of PD to identify potential biomarkers, elucidate pathological mechanisms, and explore therapeutic targets. Methods: A total of 72 mice were divided into six groups, including one control group and five PD model groups (W1-W5, representing distinct stages based on the duration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid induction). Striatal tissues were comprehensively collected, and small-molecule metabolites were detected using metabolomics techniques. Potential differential metabolite biomarkers were screened through variable importance in projection values from orthogonal partial least squares-discriminant analysis (OPLS-DA) and coefficient values from LASSO ordinal logistic regression. Results: Thirteen potential differential metabolites were identified, including Ergocalciferol, Glutaric acid, Etilefrine, and Guanine, among others. Pathway enrichment analysis revealed that purine metabolism emerged as the most significantly perturbed pathway. Additionally, receiver operating characteristic curve analysis demonstrated that the biomarker panel composed of these 13 metabolites effectively distinguished different stages of PD. Conclusion: The striatum exhibits distinct metabolic profiles at different stages of PD, with purine metabolism showing the most pronounced alterations. The characteristic metabolites and metabolic pathways identified in this study contribute to elucidating the pathophysiological features of PD and may guide precision therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.